{"id":1365,"date":"2026-03-22T15:00:00","date_gmt":"2026-03-22T15:00:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1365"},"modified":"2026-03-19T19:56:48","modified_gmt":"2026-03-19T19:56:48","slug":"tesamorelin-peptide-ghrh-analogue-research-guide","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/","title":{"rendered":"Tesamorelin Peptide: GHRH Analogue Research, Mechanism of Action & Metabolic Studies"},"content":{"rendered":"

For laboratory and research use only. Not for human consumption.<\/em><\/p>\n\n

Here’s a problem that frustrated endocrine researchers for decades: native growth hormone-releasing hormone breaks down in minutes. Literally minutes. You inject it, enzymes chew it apart, and it’s gone before it can do much of anything useful. That’s why Theratechnologies Inc. in Montreal started tinkering with the molecule in the first place \u2014 and what they came up with was tesamorelin<\/a>, a 44-amino acid GHRH analogue with one clever tweak that changes everything.<\/p>\n\n

That tweak? A trans-3-hexenoic acid group bolted onto the N-terminal tyrosine. It sounds minor. It isn’t. That single lipophilic modification makes the compound resist the very enzymes that destroy native GHRH, and it tightens binding at the pituitary receptor. The result is one of the most studied growth hormone secretagogues in the research literature \u2014 with Phase 3 data, controlled trials, and head-to-head comparisons against compounds like sermorelin<\/a> and CJC-1295<\/a>.<\/p>\n\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n